CN Patent

CN114671889A — 一种取代三环吡啶酮衍生物的晶型及其制备方法

Assigned to Jiangsu Vcare Pharmatech Co Ltd · Expires 2022-06-28 · 4y expired

What this patent protects

本发明涉及一种取代三环吡啶酮衍生物的晶型及其制备方法，具体地涉及玛巴洛沙韦中间体7‑(苄氧基)‑3,4,12,12a‑四氢‑1H‑[1,4]噁嗪[3,4‑c]吡啶并[2,1‑f][1,2,4]三嗪‑6,8二酮的晶型，通过溶剂筛选得到晶型A，该晶型在高湿条件下稳定不易结块，且用该晶型为原料进行拆分得到的产物手性纯度高。

USPTO Abstract

本发明涉及一种取代三环吡啶酮衍生物的晶型及其制备方法，具体地涉及玛巴洛沙韦中间体7‑(苄氧基)‑3,4,12,12a‑四氢‑1H‑[1,4]噁嗪[3,4‑c]吡啶并[2,1‑f][1,2,4]三嗪‑6,8二酮的晶型，通过溶剂筛选得到晶型A，该晶型在高湿条件下稳定不易结块，且用该晶型为原料进行拆分得到的产物手性纯度高。

Drugs covered by this patent

Patent Metadata

Patent number
CN114671889A
Jurisdiction
CN
Classification
—
Expires
2022-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Vcare Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.